Richard Williams

Associate Professor

Richard Williams has worked at the Kennedy Institute of Rheumatology since 1989 and was a Senior Lecturer (2007-2011) and then Reader (2011-2012) at Imperial College London before joining the University of Oxford.

He is also a Visiting Lecturer at University College London, Queen Mary University of London and the London School of Hygiene and Tropical Medicine and was recently appointed as an Editor of Arthritis Research and Therapy.

He has established an internationally recognised reputation in translational research and his early studies were instrumental in the development of TNF blocking biologics.

He has carried out numerous projects with British and overseas industrial partners, including Merck, Pfizer, GSK, UCB, Schering, Celgene and J&J and has led an MRC DPFS project on rheumatoid arthritis.

Key publications

Selective tumor necrosis factor receptor I blockade is antiinflammatory and reveals immunoregulatory role of tumor necrosis factor receptor II in collagen-induced arthritis.
Journal article

McCann FE. et al, (2014), Arthritis & rheumatology (Hoboken, N.J.), 66, 2728 - 2738
Treg cell function in rheumatoid arthritis is compromised by ctla-4 promoter methylation resulting in a failure to activate the indoleamine 2,3-dioxygenase pathway.
Journal article

Cribbs AP. et al, (2014), Arthritis & rheumatology (Hoboken, N.J.), 66, 2344 - 2354
Incomplete response of inflammatory arthritis to TNFα blockade is associated with the Th17 pathway.
Journal article

Alzabin S. et al, (2012), Annals of the rheumatic diseases, 71, 1741 - 1748
Indoleamine 2,3 dioxygenase-mediated tryptophan catabolism regulates accumulation of Th1/Th17 cells in the joint in collagen-induced arthritis.
Journal article

Criado G. et al, (2009), Arthritis and rheumatism, 60, 1342 - 1351
Blockade of tumor necrosis factor in collagen-induced arthritis reveals a novel immunoregulatory pathway for Th1 and Th17 cells.
Journal article

Notley CA. et al, (2008), The Journal of experimental medicine, 205, 2491 - 2497

Recent publications

T cell activation Rho GTPase activating protein (TAGAP) is upregulated in clinical and experimental arthritis.
Journal article

Arshad M. et al, (2018), Cytokine, 104, 130 - 135
Therapy: Arming the regulators - new strategies to treat autoimmunity.
Journal article

Williams RO. and Tseng W-Y., (2018), Nature reviews. Rheumatology, 14, 188 - 189
ILDR2 Is a Novel B7-like Protein That Negatively Regulates T Cell Responses.
Journal article

Hecht I. et al, (2018), Journal of immunology (Baltimore, Md. : 1950), 200, 2025 - 2037
TNFα in the regulation of Treg and Th17 cells in rheumatoid arthritis and other autoimmune inflammatory diseases.
Journal article

Bystrom J. et al, (2018), Cytokine, 101, 4 - 13
Association of rs182429 variant in TAGAP with rheumatoid arthritis in Pakistani population
Journal article

Arshad M. et al, (2017), Meta Gene, 14, 59 - 63

More publications